Horien Biotech (7814-TW) was listed on the OTC market today (16th) at NT$28.47 per share. With frequent good news from overseas markets and a surge in revenue in June, the company defied the weakness of the overall market and surged to a high of NT$32.15 in the morning, with an increase of more than 10%, successfully staging a honeymoon period.

Horien Biotech opened at NT$32, reaching a high of NT$32.15, a gain of over 10%. As of 10:30 AM, the stock was trading at NT$30.95, up over 8%, with a trading volume of approximately 500 shares.

 Benefiting from the growth in Taiwan and overseas markets, Horien Biotech's June revenue reached NT$14.7 million, a 2.09-fold year-on-year increase. Overseas markets have seen frequent successes, with the company recently obtaining three high-risk medical device market licenses in Thailand. It is also expected to obtain Class 3 medical device licenses in the Philippines and Vietnam soon, completing its Southeast Asian market layout. Furthermore, its innovative bio-ink products are expected to be exported to the European market by the end of this year, further expanding its international footprint to Europe and the United States.

 In the research and development of high-end innovative medical devices, Horien Biotech's self-developed "biodegradable ureteral stent" has already obtained a Taiwanese invention patent and is expected to obtain invention patents in the United States, Europe, and China soon. In addition, collagen regeneration patches have also entered the trial production stage.

Report Link: